ENTITY

Obsidian Therapeutics (OBX US)

2
Analysis
Health Care • United States
Obsidian Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops engineered tumor infiltrating lymphocyte (TIL) cell therapies for solid tumors, utilizing its proprietary cytoDRiVEā„¢ platform. Its lead product candidate, amsoki-cel, is currently in Phase 2 clinical trials for advanced melanoma and Phase 1 for non-small cell lung cancer, having demonstrated a 67% objective response rate in melanoma patients during a Phase 1/2 trial.
more
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
x